Kringle Pharma, Inc. (TYO:4884)
Japan · Delayed Price · Currency is JPY 380.00
+3.00 (0.80%)
Feb 17, 2026, 10:41 AM JST
Kringle Pharma Company Description
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan.
The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury.
Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
Kringle Pharma, Inc.
| Country | Japan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Kiichi Adachi |
Contact Details
Address: Nakanoshima Qross Research & Development Center Kita, 530-0005 Japan | |
| Phone | 81 7 2641 8739 |
| Website | kringle-pharma.com |
Stock Details
| Ticker Symbol | 4884 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | JPY |
| ISIN Number | JP3270790003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kiichi Adachi | Chief Executive Officer |